Objective MicroRNAs are known to regulate 60% of genes at post translational level. MicroRNAs including Micro RNA-29 family play a vital role in cellular activities and have validate role in numerous metabolic disorders inclusive of diabetes mellitus and its complications. While micro RNA profile changes years before the occurrence of disease. This cross-sectional study was conducted in non-diabetic adults of diabetic and non-diabetic parents to explore the early changes in expression of micro RNA-29 family as it can be served as early biomarker of type 2 diabetes in non-diabetic adults. This study was conducted from January 2019 to January 2021. Micro RNA was extracted from plasma of 50 participants and expression was compared through qPCR. While data was analyzed through SPSS version 21.0. Results 29a and 29b had lower expression in participants with family history of DM compared to those having no family history of DM (P < 0.0001). While micro RNA 29c was found to be significantly higher in participants with positive family history of type 2 diabetes as compared to those without family history of diabetes (P = 0.001).

Myxopapillary ependymoma (MPE), a rare pathological subtype of ependymoma which shows predilection for middle-aged adults between third and fifth decades of life. It is a benign tumor that primarily occurs at filum terminale of spinal cord with a rare possibility to metastasize to the brain. Primary intracranial MPEs have been reported only rarely. Two-year-old child presented with a space-occupying lesion in fourth ventricle. Based on clinical and radiological findings, particularly owing to patient's age differential diagnosis of medulloblastoma was considered. Biopsy followed by histopathological and immunohistochemical analysis yielded diagnosis of primary intracranial myxopapillary ependymoma. In conclusion, MPEs can occur anywhere in intracranial space and in any age group. Despite their indolent behavior, their metastatic potential necessitates thorough investigation to rule out former before establishing diagnosis of primary intracranial MPE.